Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.